Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 181 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo and ketamine Clear all
Terminated Phase 2 Interventional

Ketamine for OUD and Suicidal Ideation in the ED

NCT06111339
View directory record Official record
Conditions
Opioid Use Disorder, Suicidal Ideation
Interventions
Ketamine, Saline Solution
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Glutamatergic Mechanisms: Aim2

NCT05401227
View directory record Official record
Conditions
Healthy
Interventions
Ketamine, Ts-134 or XT, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

Ketamine Treatment of Youth Suicide Attempters

NCT04763343
View directory record Official record
Conditions
Suicide, Attempted
Interventions
Ketamine Hydrochloride, Saline, CAMS Therapy
Drug · Behavioral
Lead sponsor
Tatiana Falcone, MD
Other
Eligibility
14 Years to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Phase 4 Interventional

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression

NCT06317636
View directory record Official record
Conditions
Chronic Pain, Depression
Interventions
Ketamine, Normal saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

NCT07716098
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Redlands, California • San Diego, California • Marietta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Treatment Resistant Depression (Pilot)

NCT01179009
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine, Clonidine, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

NCT03246971
View directory record Official record
Conditions
Acute Pain, Bunion, Abdominoplasty
Interventions
Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Not applicable Interventional Results available

Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain

NCT00720330
View directory record Official record
Conditions
Pain, Nausea
Interventions
ropivacaine, Lidocaine/Ketamine, placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

NCT03149991
View directory record Official record
Conditions
Depression
Interventions
Brexpiprazole, Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Garden Grove, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy

NCT02452060
View directory record Official record
Conditions
Pain, Postoperative Depression
Interventions
Ketamine, Placebo Comparator
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

NCT02541396
View directory record Official record
Conditions
Acute Pain
Interventions
Wafermine, Oxycodone, Placebo
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

ACL Repair and Multimodal Analgesia

NCT01868425
View directory record Official record
Conditions
Pain
Interventions
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Withdrawn Not applicable Interventional

The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl

NCT01825083
View directory record Official record
Conditions
Hypercarbia
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 2 Interventional

Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department

NCT07868913
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning
Drug · Other · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Not listed Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
View directory record Official record
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 13, 2026, 7:14 PM EDT
Withdrawn Phase 4 Interventional

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

NCT03226080
View directory record Official record
Conditions
Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions
Rocuronium, Sugammadex, Normal saline
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

NCT03065335
View directory record Official record
Conditions
Healthy Volunteer, Major Depressive Disorder, Depression
Interventions
Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
Drug · Other · Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed No phase listed Observational

Long Term Follow Up KET-PD

NCT06164756
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Phase 4 Interventional

Ketamine as a Supplement to Local Anesthesia for Minor Procedures

NCT06284473
View directory record Official record
Conditions
Pain, Procedural, Minor Laceration, Abscess
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Loyola University
Other
Eligibility
7 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department

NCT02916927
View directory record Official record
Conditions
Pain
Interventions
Ketamine IV Infusion, Ketamine IV push
Drug
Lead sponsor
Alameda Health System
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

NCT03274453
View directory record Official record
Conditions
Spinal Fusion
Interventions
Ketamine, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 13, 2026, 7:14 PM EDT
Not listed Phase 3 Interventional

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

NCT03396601
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Hollywood, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 13, 2026, 7:14 PM EDT